Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving biomarkers. The trials were global, involved ...

Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...

(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its ...

Alzheimer’s patients have received discouraging news after the release of results from a major study. Novo Nordisk confirmed that its Alzheimer’s treatment did not show a “statistically significant” ...

Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in ...

WashU researchers have created a model that can seemingly predict a person's symptoms of Alzheimer's within a few years.